News

Windward Bio Initiates Global Phase 2 Asthma Trial of WIN378, a Potential Best-in-Disease, Long-Acting, Anti-TSLP Monoclonal Antibody
Phase 2 POLARIS trial will evaluate the dosing, safety, and efficacy of WIN378 in patients with asthma, with a first data readout expected in mid-2026WIN378 has the potential to be the first-to-market ...